Oscient Pharmaceuticals (OSCI) Inactive 10-Q2006 Q1 Quarterly report

Filed: 10 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abnormal, accredited, Advisory, ARB, assumption, award, bad, behavior, calculate, calculated, calculating, certainty, Chapter, clarify, commensurate, Committee, consummate, consummation, consumption, convene, convening, curve, daily, de, deduct, designee, diagnosed, dialogue, distinct, dividend, Dominick, doubt, entail, entity, Error, ESPP, examining, external, faith, fashion, feasible, feet, forecast, forfeiture, freight, frequently, front, implied, incidence, indefinite, instance, invoice, lessor, licence, likelihood, long, measurement, mg, midpoint, nontransferable, notice, notification, permanent, pivotal, point, predecessor, principle, profile, pronouncement, protest, provision, randomly, recoverability, recoverable, rejected, removed, repaid, repayment, satisfy, shortage, simplified, slight, spending, spoilage, square, stay, strength, sublicense, sublicensed, sublicensing, summary, surrendered, temporary, treatingClostridium, twelve, UK, unaffiliated, uncollectible, undiscounted, unissued, unrecognized, unrestricted, wasted, whichever, world, worldwide

Removed: acceleration, addressed, Agencourt, agree, allocated, Androgen, announced, approach, attained, attempt, back, Beckman, bioMerieux, Bioscience, biotechnology, block, carry, category, cautioned, chargeback, computed, concentrate, conclusion, Concurrent, confirmed, consent, constituted, cooperating, Coulter, customary, cycle, Database, delivered, deposit, diagnostic, diarrhea, diligent, discretion, dispute, distributed, entitled, equaled, evaluate, evolution, execution, fact, FIFO, flouroquinolone, fulfilled, fully, funded, gatifloxacin, goal, guaranteed, hold, hospitalized, IIa, ImmuCell, initiation, intent, labor, lapse, maximum, mix, NDA, Nick, nonaffiliated, opposed, originally, outcome, outplacement, overhead, PathoGenome, possession, preliminary, prevention, pricing, privately, prosecute, quality, reacquire, ready, realize, Receptor, reexamination, reexamined, refilled, regular, renew, representative, restate, retrospective, Selective, shift, software, Squibb, suit, target, Tequin, thirteen, timetable, transferred, treatClostridium, typically, vaccine, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

OSCI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

OSCIENT PHARMACEUTICALS CORPORATION

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report of Oscient Pharmaceuticals Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission (the “Report”), I, Steven M. Rauscher, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



By:		/s/ STEVEN M. RAUSCHER
		Steven M. Rauscher President and Chief Executive Officer

		Dated: May 10, 2006